BIOTRONIK Blog

Explore our latest insightful interviews and articles

Patient reading on the iPad

Blog Stories

Filter and Search

51 blog articles
Blog

Mindfulness Isn’t Just a Buzzword at BIOTRONIK

With 2023 upon us, BIOTRONIK employees are no exception to the kind of motivated goal-setting we often see at this time of year. Whether it’s more sports, a more mindful approach to everyday life, or to quit smoking—it’s important to have as much support as possible. That’s why BIOTRONIK’s Health Program 2023 will work to empower employees to achieve their health-related goals. 2023’s edition places a special focus on improving mental health at work, alongside the company’s work to promote physical health.
Blog

Myth or Fact? Your Device Security Questions Answered

While in office as US Vice-President, Dick Cheney had the remote monitoring function of his pacemaker turned off over concerns a malicious hacker could access his device. In 2012, an episode of the TV drama Homeland depicts a faraway terrorist hacking into the fictional US Vice-President’s pacemaker and assassinating him. It may have made for thrilling TV, but is successful malicious hacking of a cardiac device possible in real life?

Subscribe for our News

I prefer to be contacted by
*Fields are mandatory.

Latest Press Releases

Show all press releases
BUELACH, Switzerland
Press Release

First Patient Enrolled in Leave Nothing Behind-Trial Comparing Drug-Coated Balloon-Based Strategy to Drug-Eluting Stents in Chronic Total Occlusion Patients

Today BIOTRONIK announces the enrollment of the first patient in the Leave Nothing Behind-Trial. The first implantation was performed by Dr. Mohamed Ayoub at the Heart and Diabetes Center North Rhine-Westphalia, Germany. The trial aims to demonstrate the non-inferiority of drug-coated balloons (DCB) or DCBs in combination with Resorbable Magnesium Scaffolds (RMS) compared to drug-eluting stents (DES) in chronic total occlusions (CTO) in percutaneous coronary interventions (PCI). The prospective, single-center, single-blind, randomized trial evaluates the efficacy of the Pantera ® Lux ® DCB and
PARIS, France
Press Release

BIOMAG-I Data Shows No New Events between Two and Three Years in Target Lesion Failure with Freesolve Resorbable Magnesium Scaffold

New results from the BIOMAG-I first-in-human trial demonstrated an excellent safety and efficacy profile for Freesolve ®, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS) at three years follow-up. Prof. Dr. Michael Haude presented these new data at the EuroPCR 2025 conference in Paris. At the 36-month follow-up, the target lesion failure (TLF) rate remained at 3.5%, consisting of four cases of clinically driven target lesion revascularization (CD-TLR), of which only one event occurred beyond the resorption period of the scaffold. No cases of target-vessel myocardial infarction
BERLIN, Germany
BIOTRONIK Driving the Future of Active Device Business

BIOTRONIK Driving the Future of Active Device Business

BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare. Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next

Press Contact